Notice for dabrafenib (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
dabrafenib
Date of review outcome
Lapse date
Type
Priority review
Indication
Dabrafenib, in combination with trametinib, is indicated for the adjuvant treatment of patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
Registration date